Ranbaxy posts $210 mn net profit
May 11th, 2010 - 6:52 pm ICT by IANSNew Delhi, May 11 (IANS) Pharma major Ranbaxy Laboratories Tuesday reported a consolidated net profit of $210 million (Rs.963.1 crore) in the January-March quarter of 2010 against a loss of $153 million (Rs.761 crore) in the corresponding period last year.
“Solid growth in key geographies, along with optimal delivery value from first-to-file opportunities in the United States, ensured that we achieved yet another quarter of strong operational performance,” said Atul Sobti, the company’s chief executive.
The firm’s consolidated net sales grew by 65 percent to $542 million (Rs.2,490 crore) in the quarter from $313 million (Rs.1,558 crore) a year ago.
Sobti said the company will launch anti-diabetic drug Actos in the US by 2012.
Ranbaxy, majority owned by Japan’s Daiichi Sankyo, had settled litigation with Japanese firm Takeda Pharmaceutical over a generic version of the medicine and received a non-exclusive royalty free licence for its US patents covering Actos.
- Ranbaxy to launch anti-diabetic drug Actos by 2012 - Mar 15, 2010
- Ranbaxy settles issue with US health regulator - Dec 21, 2011
- Infinite Computer Solutions yearly net up 35 percent - May 10, 2011
- Arun Sawhney to replace Atul Sobti as Ranbaxy CEO - Aug 13, 2010
- Usha Martin Q4 net dips almost 60 percent - May 10, 2012
- Infosys net up 27 percent in fourth quarter - Apr 13, 2012
- Malvinder Singh steps down as Ranbaxy chief executive - May 24, 2009
- Ranbaxy's full-year net profit zooms 405 percent - Feb 22, 2011
- Infosys net up 17 percent in Q4 - Apr 15, 2011
- Ranbaxy's June quarter net profit falls by 25 pc - Aug 05, 2011
- Tata Motors third quarter net profit up 40.47 percent - Feb 14, 2012
- Coal India posts 64 percent rise in net profit - Aug 13, 2011
- Sensex ends tamely, broader markets close dull (Roundup) - Apr 25, 2011
- Idea Cellular's third quarter net profit declines - Jan 23, 2012
- DLF's Q1 net profit down 55 percent - Aug 02, 2011
Tags: actos, chief executive, crore, daiichi sankyo, delivery value, diabetic drug, free licence, generic version, geographies, japanese firm, net profit, net sales, New Delhi, operational performance, optimal delivery, ranbaxy laboratories, royalty, rs 1, rs 2, us patents